These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1511 related articles for article (PubMed ID: 17063075)

  • 1. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
    Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
    Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
    Veras E; Deavers MT; Silva EG; Malpica A
    Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
    Suh-Burgmann E
    Gynecol Oncol; 2006 Dec; 103(3):841-7. PubMed ID: 16793124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
    Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
    Ann Surg Oncol; 2008 Dec; 15(12):3561-6. PubMed ID: 18820973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases.
    Lim-Tan SK; Cajigas HE; Scully RE
    Obstet Gynecol; 1988 Nov; 72(5):775-81. PubMed ID: 3173929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomyxoma peritonei: a review of 23 cases.
    Wertheim I; Fleischhacker D; McLachlin CM; Rice LW; Berkowitz RS; Goff BA
    Obstet Gynecol; 1994 Jul; 84(1):17-21. PubMed ID: 8008316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
    Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
    Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.